抗HCV抗体和抗TP抗体筛查试验的假阳性问题及对策研究进展  

The study progress of false positivity in screening assay for detecting anti-HCV antibody and anti-TP antibody and its strategy

作　　者：陈存存 范列英[1] 

机构地区：[1]上海市东方医院检验科,上海200120

出　　处：《检验医学》2015年第12期1167-1174,共8页Laboratory Medicine

摘　　要：酶联免疫吸附试验(ELISA)和化学发光免疫分析法(CLIA)检测抗丙型肝炎病毒(HCV)抗体和抗梅毒螺旋体(TP)抗体存在一定比例的假阳性,故需经确证试验方能报告阳性结果。确定特定检测试剂(系统)在特定人群筛查试验结果的阳性预测值达95%的信号/临界值(S/CO)比值,可作为尽可能降低ELISA或CLIA检测抗HCV抗体或抗TP抗体假阳性率和经济合理应用确证试验的对策。There is a certain proportion of false positivity in screening assay for detecting anti-hepatitis C virus（ HCV） antibody and anti-treponema pallidum（ TP） antibody by enzyme-linked immunosorbent assay（ ELISA） or chemiluminescence immunoassay（ CLIA）. Therefore,it is required to report positive results by confirmation assay. It is an alternative strategy for reducing false positive rate as far as possible in detecting anti-HCV antibody and anti-TP antibody by ELISA and CLIA and making the application of confirmation assay economic and rational by determining the signal-to-cut off（ S / CO） ratio,when the positive predictive value of screening assay results reaches 95% with certain detection reagent（ system） and in certain population.

关 键 词：抗丙型肝炎病毒抗体 抗梅毒螺旋体抗体 筛查试验 假阳性 确证试验 

分 类 号：R446.61[医药卫生—诊断学]